Cortagen Protocol: Complete Cycling & Dosing Guide

Overview

Cortagen (Lys-Glu), a synthetic dipeptide bioregulator derived from brain tissue research, functions as a neuroprotective and neuroregulatory compound. Unlike classical pharmaceuticals that work through receptor-ligand interactions, Cortagen penetrates cell nuclei and modulates gene expression by interacting with chromatin, upregulating neurotrophic protein synthesis and restoring age-related neuronal decline.

The compound is available through two primary administration routes: subcutaneous injection (5-10 mg/day) and oral administration (10-20 mg/day). While developed and clinically validated in Russia and Eastern Europe, Cortagen remains a research compound in Western markets with limited large-scale clinical trial data, though Russian studies demonstrate a favorable safety profile with predominantly mild, transient side effects.

This protocol guide provides evidence-based dosing strategies, cycling frameworks, and practical administration guidance for individuals seeking to optimize Cortagen's neuroprotective and neuroregulatory effects.

Standard Protocol: Foundational Cycling Framework

Recommended Dosing by Route

Subcutaneous Injection:

• Standard dose: 5-10 mg once daily
• Lower end (5 mg): Ideal for initial tolerance assessment and maintenance phases
• Upper end (10 mg): Appropriate after 1-2 weeks of adaptation, for sustained cycling

Oral Administration:

• Standard dose: 10-20 mg once daily
• Lower end (10 mg): Initial tolerance phase and maintenance
• Upper end (20 mg): Secondary phase dosing following adaptation period

Oral bioavailability is notably lower than injection, necessitating higher doses. Injectable routes deliver more direct neuroprotective effects but carry minor injection site reactions; oral routes offer convenience with modest GI considerations.

Standard Cycle Structure

Cycle Duration: 10-30 consecutive days

• Minimum effective cycle: 10 days (assessment and short-term neuroprotection)
• Standard cycle: 20 days (optimal risk-benefit for neuronal adaptation)
• Extended cycle: 30 days (sustained neuroprotective accumulation)

Rest Periods Between Cycles:

• Minimum 14 days off-compound
• Standard protocol: 21 days off between 20-day cycles (1:1 ratio on/off)
• Conservative approach: 30+ days off for extended cycles

Annual Administration:

• Maximum recommended: 120 days per year of active use
• Typical user: 2-3 cycles of 20 days with 21-day breaks = 80-100 days annually
• This allows sufficient rest to preserve neuroplasticity sensitivity and avoid tachyphylaxis

Goal-Specific Protocols

Protocol A: Neuroprotection & Cognitive Support (Primary Use Case)

Best For: Aging populations, post-neurological events, cognitive decline prevention

Cycle Structure:

• Duration: 20 days active
• Dosing: 5 mg/day (injection) or 10-15 mg/day (oral)
• Rest period: 21 days minimum
• Frequency: 2-3 cycles per year

Timeline:

• Days 1-3: Lower adaptation phase (observe for transient headache or activation effects)
• Days 4-20: Steady neuroprotective accumulation
• Days 21+: Recovery and neuronal consolidation during rest

Monitoring: Track baseline cognitive markers (memory recall, processing speed, attention span) before cycle initiation. Subtle improvements typically manifest by day 10-14 of active use.

Protocol B: Nerve Regeneration & Injury Recovery (Limited Evidence)

Best For: Post-surgical nerve damage, peripheral neuropathy (animal evidence suggests potential)

Cycle Structure:

• Duration: 10-15 days active
• Dosing: 10 mg/day (injection recommended for direct tissue delivery)
• Rest period: 21-30 days
• Frequency: 1-2 cycles per year

Rationale: Animal studies demonstrate 27-40% improvements in nerve conduction velocity and growth rates. Shorter, more intensive cycles may optimize recovery phases.

Important Note: This remains investigational in humans. No clinical trials exist. Use only under medical supervision for diagnosed nerve injuries.

Protocol C: Longevity & Aging Optimization (Mechanistic Evidence Only)

Best For: Healthy aging, chromatin structure optimization, cellular longevity markers

Cycle Structure:

• Duration: 20-30 days active
• Dosing: 5 mg/day (injection) — lower end for chronic cycling
• Rest period: 30-45 days
• Frequency: 2-3 cycles per year on conservative schedule

Extended Timeline Example:

• Months 1-2: First 20-day cycle + 30-day rest
• Months 3-4: Second 20-day cycle + 30-day rest
• Month 5: Rest/assessment month
• Repeat annually

In vitro evidence shows Cortagen induces deheterochromatinization and ribosomal gene activation in aged human lymphocytes, suggesting epigenetic-level optimization. Extended cycles with longer rest periods may optimize this mechanism.

How to Administer: Step-by-Step Instructions

Injectable Administration (Subcutaneous)

Materials Needed:

• Cortagen powder (vial)
• Bacteriostatic saline or sterile saline (reconstitution medium)
• 1 mL syringe with 29-31 gauge needle
• Alcohol prep pads
• Sharps container

Reconstitution Protocol:

1. Calculate total volume needed for your cycle (e.g., 20 days × 10 mg = 200 mg total)
2. Draw bacteriostatic saline into syringe
3. Inject saline slowly into Cortagen vial
4. Remove syringe and gently roll vial for 30-60 seconds (do not shake vigorously)
5. Wait 2-3 minutes for complete dissolution
6. Draw calculated daily dose into fresh syringe
7. Store reconstituted solution at 2-8°C (refrigerator)
8. Reconstituted solution remains stable for 14-21 days

Daily Injection Procedure:

1. Remove vial and syringe from refrigeration 5 minutes before injection
2. Clean injection site (abdomen, upper thigh, or deltoid) with alcohol pad
3. Pinch skin fold gently; inject needle at 45-degree angle into subcutaneous tissue
4. Inject solution slowly over 10-15 seconds
5. Withdraw needle and apply light pressure with clean gauze for 30 seconds
6. Rotate injection sites daily to minimize reactions

Storage: Refrigerate at 2-8°C; do not freeze. Protect from light. Reconstituted solution: 14-21 days maximum.

Oral Administration

Preparation:

• Cortagen tablets or capsules typically dose 10-20 mg per dose
• Take once daily with or without food (though with food may reduce mild GI discomfort)
• Swallow whole; do not crush or divide

Timing: Consistent daily timing (morning or evening) optimizes neuroregulatory effects.

Storage: Room temperature (15-25°C), away from moisture. Keep in original packaging.

Cycle Example: Week-by-Week Schedule

20-Day Standard Neuroprotection Cycle (Injectable)

Dose: 5 mg/day subcutaneous injection

Month 2 (Optional Second Cycle): Repeat identical structure. Spacing ensures no tachyphylaxis development.

What to Expect: Timeline of Effects

Days 1-3 (Initial Activation Phase)

• Common experience: Mild transient headache, slight fatigue, mild dizziness
• Mechanism: Neuronal activation and chromatin remodeling initiation
• What's normal: These effects are expected markers of neuronal engagement
• What's concerning: Severe headache, significant dizziness (discontinue; consult provider)

Days 4-7 (Early Adaptation)

• Cognitive changes: Subtle sharpening of focus; improved processing speed
• Physical sensations: Resolution of initial headache; baseline energy normalizes
• Injection site: Minimal redness if subcutaneous; resolves within 24-48 hours
• Marker of success: Headache resolution indicates successful neuronal adaptation

Days 8-15 (Accumulation & Consolidation)

• Memory function: Noticeable improvement in recall; clearer thought formation
• Mood: Mild cognitive/attentional lift; slight mood stabilization possible
• Endurance: Mental clarity sustains longer into work/study sessions
• What to assess: Compare baseline cognitive markers (memory tests, processing speed tasks)

Days 16-20 (Sustained Benefit)

• Peak effect window: Maximum neuroprotective accumulation
• Consistency: Cognitive benefits plateau; improvements stabilize
• Sustainability: Effects felt consistent across all functional domains
• Marker of effectiveness: Ability to sustain focus and recall throughout day

Days 21-41 (Off-Cycle Recovery)

• Neuronal consolidation: Brain tissue consolidates activated genes and neurotropic adaptations
• Sensitivity preservation: Rest period prevents receptor/epigenetic downregulation
• Expected timeline: Benefits remain elevated for 7-14 days post-cycle; gradual return to baseline over remaining rest period
• Assessment window: Days 21-35 ideal for measuring sustained cognitive gains

Common Protocol Mistakes

Mistake 1: Running Cycles Too Frequently

Problem: Cycling on/off every 10 days without adequate rest periods causes tachyphylaxis—the nervous system downregulates responsiveness to maintain homeostasis.

Solution: Maintain minimum 14-day rest, preferably 21+ days. Annual caps of 120 active days prevent chronic receptor desensitization.

Mistake 2: Excessive Dosing

Problem: Escalating beyond 10 mg/day (injection) or 20 mg/day (oral) increases side effects without proportional benefit.

Common error: Assuming "more equals faster results." Neuroprotection is epigenetic, not dose-dependent beyond threshold.

Solution: Standard dosing (5 mg injectable, 10-15 mg oral) optimizes the risk-benefit ratio. Extend cycle length rather than escalate dose.

Mistake 3: Inconsistent Administration Timing

Problem: Variable injection timing disrupts neuronal gene expression rhythms; oral doses taken sporadically reduce steady-state neuroprotection.

Solution: Fixed daily timing (morning or evening) maximizes chromatin remodeling consistency.

Mistake 4: Inadequate Reconstitution Protocol

Problem: Vigorous shaking instead of gentle rolling causes peptide denaturation; bacterial contamination from poor aseptic technique renders solution ineffective.

Solution: Use bacteriostatic saline; roll vials gently; maintain sterile technique throughout. Discard any reconstituted solution after 21 days.

Mistake 5: Skipping Initial Tolerance Assessment

Problem: Jumping directly to 10 mg/day masks individual sensitivity to transient headache or activation effects.

Solution: Begin at 5 mg/day for first cycle; assess tolerance before dose escalation in subsequent cycles.

How to Stack with Other Compounds

Cortagen's neuroprotective mechanism (nuclear chromatin interaction) operates distinctly from receptor-based compounds, allowing complementary stacking.

Stack A: Cortagen + Epithalon (Synergistic Neuroprotection)

Rationale: Epithalon (Ala-Glu-Asp-Pro) modulates pineal gland function; Cortagen directly supports cortical neuroprotection. Complementary mechanisms.

Protocol:

• Cortagen: 5 mg/day subcutaneous (days 1-20)
• Epithalon: 10 mg/day subcutaneous (days 1-10, then 5-day break, days 16-20)
• Rest: 21 days off both compounds
• Benefit: Enhanced cognitive + endocrine neuroprotection

Stack B: Cortagen + Nootropic Support (Enhanced Cognitive Function)

Stacking with: Racetams (Piracetam), Choline sources, Magnesium L-threonate

Protocol:

• Cortagen: 5-10 mg/day (injectable or oral)
• Nootropic: Standard dosing per compound guidelines
• Timing: Both taken simultaneously (morning) for synergistic neuroplasticity support
• Rationale: Cortagen upregulates neurotrophic gene expression; nootropics enhance acetylcholine/membrane fluidity—non-overlapping mechanisms

Stack C: Cortagen + N-Acetyl Cysteine (Oxidative Stress Management)

Rationale: Cortagen reduces lipid peroxidation markers; NAC further supports antioxidant capacity.

Protocol:

• Cortagen: 5-10 mg/day (days 1-20)
• NAC: 600-1200 mg/day (taken separately, 12 hours apart to avoid chelation)
• Benefit: Additive neuroprotection against oxidative stress

Compounds NOT to Stack:

• Avoid concurrent peptides (Thymosin Alpha 1, other immunomodulatory peptides): Risk of over-stimulating immune response without human trial safety data
• Avoid during active infection: Immune modulation may complicate infection clearance

Protocol Quick Reference Table

Signs It's Working & Adjustment Framework

Positive Indicators (Cycle is Effective)

• Cognitive markers: Improved memory recall; faster information processing
• Focus sustainability: Ability to concentrate extends 30-60 minutes beyond baseline
• Clarity: Mental fog decreases; thought organization sharpens
• Mood stability: Subtle elevation in mental resilience; reduced cognitive fatigue
• Timeline: These improvements stabilize by day 12-15

When to Adjust Dosing

If minimal cognitive benefit by day 15:

• Increase dose by 2.5-5 mg/day in next cycle (but don't exceed 10 mg injectable, 20 mg oral)
• Extend cycle to 25-30 days to allow greater accumulation
• Ensure consistent daily timing and proper reconstitution

If side effects persist beyond day 5:

• Reduce dose by 2.5 mg/day
• Consult medical provider if headache persists beyond day 7

If cognitive gains plateau in third consecutive cycle:

• Extend rest period to 30-45 days
• Consider stacking with complementary neuroprotective compound
• Reset to lower dose in subsequent cycle

Disclaimer

This protocol guide is educational content intended to inform individuals about Cortagen administration frameworks based on available research data and practical application. It is not medical advice, clinical guidance, or a substitute for professional medical consultation.

Cortagen remains a research compound with limited large-scale Western clinical trial data. Safety profiles derive primarily from Russian and Eastern European studies. Before initiating Cortagen use, consult with a qualified healthcare provider, particularly if you have:

• Autoimmune conditions
• Known peptide sensitivities or allergies
• Neur